Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review

Konskie,,Poland,-,February,24,,2024:,Sarepta,Therapeutics,Company,Logo

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, effective July 22.

This reversal follows Sarepta's initial refusal to halt distribution despite a Food and Drug Administration (FDA) request amid safety concerns linked to patient deaths.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.